NCT06049940View on ClinicalTrials.gov

Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

PHASE3CompletedINTERVENTIONAL

Enrollment

1,260

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

October 26, 2023

Study Completion Date

March 22, 2024

Conditions

Tetanus

Interventions

BIOLOGICAL

Investigational tetanus vaccine, adsorbed

The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.

BIOLOGICAL

Control tetanus vaccine, adsorbed

The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.

Trial Locations (1)

450016

Liangyuan District Center for Disease Control and Prevention, Shangqiu

All Listed Sponsors

lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY

NCT06049940 - Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population | Biotech Hunter | Biotech Hunter